This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
It's Not Just About Glycemic Control: Once-Weekly GLP-1 RAs and the Diversity of T2DM Patients

It's Not Just About Glycemic Control: Once-Weekly GLP-1 RAs and the Diversity of T2DM Patients



Time to Complete

1 hour


August 12, 2019


August 11, 2020
Add to Queue

Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM

Accredited Provider

Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Novo Nordisk

Program Description

Many clinicians who manage the care of patients with type 2 diabetes mellitus (T2DM) still lack confidence in the use of GLP-1 receptor agonists (GLP-1 RAs). Despite clear recommendations from national and international guidelines about the safety and efficacy of GLP-1 RAs, clinicians need further guidance on the appropriate selection of these agents for the multidimensional care of a diverse population of T2DM patients.

This activity is the last in a series of 4 designed to bring clinicians up-to-date on the rapidly evolving landscape of treatment for T2DM. Two internationally renowned experts talk about the “now” and the “new” generation of GLP-1 receptor agonists (GLP-1 RAs), focusing on once-weekly formulations, their comparative performance with respect to glycemic efficacy, weight loss, safety, and cardiovascular outcomes, and how the latest, 2018 clinical practice guidelines by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), promise to impact clinical decision-making, emphasizing proper patient selection and the importance of shared decision-making.

Intended Audience

Primary care (family medicine/internal medicine) MDs, DOs, NPs, PAs, and other providers who care for patients with diabetes.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Compare the current and next generation of once-weekly GLP-1 RAs regarding glycemic efficacy, weight-loss efficacy, and safety
  • Evaluate long-acting GLP-1 RAs in patient with T2DM who do not meet glycemic goals
  • Engage in a therapeutic alliance with patients applying the principles of shared decision-making in a collaborative model of diabetes care
  • Conflict Of Interest Disclosure Policy

    In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.


    Professor Stephen C. Bain, BA, MA, MBBS, MD, PRCP
    Professor of Medicine (Diabetes)
    Swansea University Medical School
    Sketty Swansea, United Kingdom

    Prof. Bain receives honoraria, research sponsorship, or grants from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cellnovo, Diartis Pharmaceuticals, Eli Lilly & Co., GlaxoSmithKline, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Servier Laboratoires, and Takeda. He also receives support for the development of educational programs from Cardiff University,, Elsevier, Medscape, OmniaMed, and OnMedica. Dr. Bain is a Stock/Shareholder of Glycosmedia, which carries sponsorship declared on site. Additionally, he is a consultant for All-Wales Medicines Strategy Group and the National Institute for Health and Care Excellence.

    Professor Michael A. Nauck, MD
    Diabetes Centre Bochum-Hattingen
    Medical Department I
    St. Josef-Hospital
    Bochum, Germany

    Prof. Nauck is a consultant for Eli Lilly & Co., Menarini/Berlin-Chemie, Merck Sharp & Dohme, and Novo Nordisk. He receives research support (provided to his institution) from AstraZeneca, Merck Sharp & Dohme, and Novo Nordisk. Dr. Nauck is also on the speakers’ bureaus of AstraZeneca, Eli Lilly & Co., Medscape, Menarini/Berlin-Chemie, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Sun Pharma.

    Accredited Provider Disclosure

    Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.




    AMA PRA Category 1 Credit(s)TM

    Accreditation Statement

    Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation Statement

    Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Additional Credit Information

    Physician Assistant Continuing Education
    AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.

    Nurse Practitioner Continuing Education
    AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

    Disclosure of Unlabeled Use

    This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education (HME), or Novo Nordisk. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    If you have any questions relating to the CME accreditation of this activity, please contact HME at

    If you have any questions relating to your certificate or other issues with this activity, please contact


    To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

    Privacy Policy


    Hardware and Software Requirements
    • A computer with an internet connection
    • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
    • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
    Add to Queue